The Whole New World of SGLT-2 Inhibitors: Looking into the Cardio-Kidney-Metabolic Space

This educational activity will provide an overview of CKM syndrome and evidence supporting early screening and treatment. The latest data from all landmark clinical trials, systematic reviews, and meta-analyses demonstrating the benefit of SGLT2 inhibitors on cardiorenal outcomes and clinical trials currently underway to identify potential emerging areas for SGLT2 inhibitor benefit will be presented. A review of the latest clinical practice guidelines for the use of SGLT2 inhibitors in heart failure, kidney disease, and diabetes will be shared. The activity will conclude with an exploration of interprofessional care models that address barriers and incorporate pharmacists into the initiation, titration, and monitoring of SGLT2 inhibitor therapy for patients who could benefit from treatment.

Parenteral Nutrition Quality and Safety: Tenets for Acute and Long-Term Care Patients

This educational activity will review important foundational principles of parenteral nutrition. A case-based approach that incorporates guidance for appropriate use, preparation and safe administration of short- and long-term parenteral nutrition will be incorporated. Discussion includes compatibility and stability with a focus on lipid injectable emulsions (ILEs), managing drug shortages and transitions of care, and bridging the gap between formal guideline recommendations and the use of parenteral nutrition in daily practice.

Building and Implementing a Value-Proposition for Ready-to-Administer Products

This educational activity will examine the evidence for the safety and cost-effectiveness of ready-to-administer (RTA) prefilled syringes compared to the traditional vial-and-syringe method. The data and information for building an institution-specific value proposition to persuade decision makers to adopt or expand use of RTA prefilled syringes will be discussed. Faculty will present implementation strategies for transitioning from vial and syringe to RTA prefilled syringes in different areas of the health system and in non-traditional sites.